Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Adenosquamous Carcinoma Clear all
Completed Not applicable Interventional Results available

Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00499447
View directory record Official record
Conditions
Lung Cancer
Interventions
radiofrequency ablation, radiation therapy
Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT00002823
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, vinblastine sulfate, vindesine, vinorelbine tartrate, radiation therapy
Drug · Radiation
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Other
Eligibility
18 Years to 75 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
2
States / cities
Atlantis, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00979212
View directory record Official record
Conditions
Lung Cancer
Interventions
panitumumab, carboplatin, paclitaxel, surgery
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
31
States / cities
Carmichael, California • Sacramento, California • Colorado Springs, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311
View directory record Official record
Conditions
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions
darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
64
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jun 10, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT00776100
View directory record Official record
Conditions
Lung Cancer
Interventions
clinical observation, radiation therapy
Other · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
168
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jun 10, 2026, 2:14 AM EDT
Not listed Phase 2 Interventional

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00033722
View directory record Official record
Conditions
Lung Cancer
Interventions
folic acid, lometrexol
Dietary Supplement · Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00006378
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
Morristown, New Jersey • New Brunswick, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT02186847
View directory record Official record
Conditions
Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions
Radiation Therapy, Carboplatin, Metformin, Paclitaxel
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
220
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 177 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

NCT00287963
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride, vinorelbine tartrate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jun 10, 2026, 2:14 AM EDT
Withdrawn Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00054392
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
57
States / cities
Loma Linda, California • Pomona, California • New London, Connecticut + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

NCT00006004
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Atlanta, Georgia • Des Moines, Iowa • Papillion, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00010218
View directory record Official record
Conditions
Lung Cancer
Interventions
karenitecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
44
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jun 10, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional Results available

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT01041781
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
400
States / cities
Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 3 Interventional

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00003117
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
35
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jun 10, 2026, 2:14 AM EDT
Not listed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00006458
View directory record Official record
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT00126581
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
96
States / cities
Castro Valley, California • Emeryville, California • Fremont, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 3 Interventional

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

NCT00499330
View directory record Official record
Conditions
Lung Cancer
Interventions
lobectomy, segmentectomy or wedge resection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
373
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 244 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00040794
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jun 10, 2026, 2:14 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00547443
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, sorafenib tosylate, radiation therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction

NCT00009789
View directory record Official record
Conditions
Lung Cancer
Interventions
accelerated conformational radiotherapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions
cisplatin, fluoxetine, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
42
States / cities
Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT01557959
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, pegfilgrastim, erlotinib hydrochloride, laboratory biomarker analysis, polymorphism analysis, pharmacogenomic studies, genetic linkage analysis, docetaxel
Drug · Biological · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jun 10, 2026, 2:14 AM EDT
Suspended Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

NCT04929041
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
170
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 130 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 10, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

NCT03215810
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinomas
Interventions
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2)
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jun 10, 2026, 2:14 AM EDT